Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Retevmo (selpercatinib) is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test; for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy; for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); and for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Selpercatinib (retevmo) shows an objective-response rate (ORR) ranging from 60% to 89%, a complete-response rate (CRR) between 0% and 11%, and a partial-response rate (PRR) ranging from 55% to 89%.
• Effectiveness outcomes for selpercatinib are comparable to those of pralsetinib, another RET-specific tyrosine kinase inhibitor, with no differentiation regarding their ORR, CRR, or PRR. 5. ≥Grade 3 Adverse Events: Reported in 28% to 53% of patients.
• Common Adverse Effects: Include hypertension, changes in ALT levels, QT prolongation, neutropenia, and pneumonitis.
• There is no population types or subgroups information available in the reviewed studies.